Home - Products - Others - Other Targets - RIG012

RIG012

CAS No. 2642218-43-5

RIG012( —— )

Catalog No. M36533 CAS No. 2642218-43-5

RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM (measured by NADH-coupled ATPase), and it inhibits the expression of IFN-β and ISG hRsad2.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	176	In Stock
5MG	275	In Stock
10MG	440	In Stock
25MG	702	In Stock
50MG	908	In Stock
100MG	1242	In Stock
500MG	2502	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

RIG012
Note

Research use only, not for human use.
Brief Description

RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM (measured by NADH-coupled ATPase), and it inhibits the expression of IFN-β and ISG hRsad2.
Description

RIG012 is a potent RIG-I inhibitor with an IC50 of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

2642218-43-5
Formula Weight

359.42
Molecular Formula

C23H21NO3
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 33.33 mg/mL (92.73 mM; Ultrasonic )
SMILES

C(C)C1(CC)C=2C(C=3C(C(=O)C2OCC4=CC=CC=C4)=CC=CC3)=NC1=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. David C Rawling, et al. Small-Molecule Antagonists of the RIG-I Innate Immune Receptor. ACS Chem Biol. 2020 Feb 21;15(2):311-317.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

Pomalidomide 4'-PEG2...

Pomalidomide 4'-PEG2-azide is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a linker.
Carasiphenol C

Carasiphenol C is a natural product from Carex humilis Leyss.
Isoviolanthin

Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC.

Sign In Join Free